Qunfang Zhou

6PUBLICATIONS
1CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 26, 2026
Ablation of pulmonary oligometastasis in advanced hepatocellular carcinoma treated with Lenvatinib: a retrospective multicenter study.

Ye Li, Yigong Ren, Hui Li

|Sep 16, 2024
Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.

Ruixia Li, Xiaohui Wang, Hui Li

|Sep 16, 2024
Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.

Murong Wang, Qunfang Zhou, Hui Li

|Aug 26, 2024
Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study.

Wei Wang, Ruixia Li, Hui Li

|Aug 03, 2022
Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.

Qunfang Zhou, Xiaohui Wang, Ruixia Li

|Jul 11, 2022
Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.

Qunfang Zhou, Xiaohui Wang, Ruixia Li

Pageof 1

Frequent Collaborators

3 joint publications

Xiaohui Wang